Skip to main content
main-content
Erschienen in: Die Gynäkologie 7/2022

23.06.2022 | Endometriumkarzinom | Leitthema

Früherkennung, Diagnostik, Bildgebung und Pathologie

verfasst von: Prof. Dr. Eric Steiner, Lars-Christian Horn, Theresa Mokry, Sigurd F. Lax, Doris Mayr, Wolfgang Cremer, Heinrich-Josef Prömpeler, Dieter Grab, Michael Reinhardt

Erschienen in: Die Gynäkologie | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Im Sommer 2022 erschien das erste Update der deutschen interdisziplinären S3-Leitlinie für die Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom (AWMF 032/034-OL 2.0). Dieser Beitrag ist die Zusammenfassung des Kapitels 2, „Diagnose, Früherkennung, Bildgebung und Pathologie“, mit dem Ziel, dem Leser eine Kurzfassung an die Hand zu geben. Dargestellt sind die Empfehlungen zur Diagnose und Früherkennung von Endometriumkarzinomen, ferner die Indikationen zur Bildgebung und die Anforderungen zur pathologischen Aufarbeitung.
Literatur
1.
Zurück zum Zitat Bertelli G et al (2000) Limited value of sonohysterography for endometrial screening in asymptomatic, postmenopausal patients treated with tamoxifen. Gynecol Oncol 78(3 Pt 1):275–277 CrossRef Bertelli G et al (2000) Limited value of sonohysterography for endometrial screening in asymptomatic, postmenopausal patients treated with tamoxifen. Gynecol Oncol 78(3 Pt 1):275–277 CrossRef
2.
Zurück zum Zitat Carlson J, McCluggage WG (2019) Reclassifying endometrial carcinomas with a combined morphological and molecular approach. Curr Opin Oncol 31(5):411–419 CrossRef Carlson J, McCluggage WG (2019) Reclassifying endometrial carcinomas with a combined morphological and molecular approach. Curr Opin Oncol 31(5):411–419 CrossRef
3.
Zurück zum Zitat Clarke MA, Long BJ, Del Mar Morillo A, Arbyn M, Bakkum-Gamez JN, Wentzensen N (2018) Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis. JAMA Intern Med 178(9):1210–1222 CrossRef Clarke MA, Long BJ, Del Mar Morillo A, Arbyn M, Bakkum-Gamez JN, Wentzensen N (2018) Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis. JAMA Intern Med 178(9):1210–1222 CrossRef
5.
Zurück zum Zitat Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S et al (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 31(1):12–39 CrossRef Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S et al (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 31(1):12–39 CrossRef
6.
Zurück zum Zitat Deckardt R et al (2002) Comparison of transvaginal ultrasound, hysteroscopy, and dilatation and curettage in the diagnosis of abnormal vaginal bleeding and intrauterine pathology in Perimenopausal and postmenopausal women. J Am Assoc Gynecol Laparosc 9(3):277–282 CrossRef Deckardt R et al (2002) Comparison of transvaginal ultrasound, hysteroscopy, and dilatation and curettage in the diagnosis of abnormal vaginal bleeding and intrauterine pathology in Perimenopausal and postmenopausal women. J Am Assoc Gynecol Laparosc 9(3):277–282 CrossRef
7.
Zurück zum Zitat Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O et al (2020) Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III–IV) or recurrent uterine serous carcinomas that overexpress her2/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res 26(15):3928–3935 CrossRef Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O et al (2020) Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III–IV) or recurrent uterine serous carcinomas that overexpress her2/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res 26(15):3928–3935 CrossRef
8.
Zurück zum Zitat Fung MF et al (2003) Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol 91(1):154–159 CrossRef Fung MF et al (2003) Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol 91(1):154–159 CrossRef
9.
Zurück zum Zitat Gerber B et al (2000) Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 18(20):3464–3470 CrossRef Gerber B et al (2000) Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 18(20):3464–3470 CrossRef
10.
Zurück zum Zitat Horn LC, Schnurrbusch U, Bilek K, Hentschel B, Einenkel J (2004) Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer 14:348–353 CrossRef Horn LC, Schnurrbusch U, Bilek K, Hentschel B, Einenkel J (2004) Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer 14:348–353 CrossRef
11.
Zurück zum Zitat Kakhki VR et al (2013) Diagnostic performance of fluorine 18 fluorodeoxyglucose positron emission tomography imaging for detection of primary lesion and staging of endometrial cancer patients: systematic review and meta-analysis of the literature. Int J Gynecol Cancer 23(9):1536–1543 CrossRef Kakhki VR et al (2013) Diagnostic performance of fluorine 18 fluorodeoxyglucose positron emission tomography imaging for detection of primary lesion and staging of endometrial cancer patients: systematic review and meta-analysis of the literature. Int J Gynecol Cancer 23(9):1536–1543 CrossRef
12.
Zurück zum Zitat Leone FP, Timmerman D, Bourne T, Valentin L, Epstein E, Goldstein SR et al (2010) Terms, definitions and measurements to describe the sonographic features of the endometrium and intrauterine lesions: a consensus opinion from the International Endometrial Tumor Analysis (IETA) group. Ultrasound Obstet Gynecol 35(1):103–112 CrossRef Leone FP, Timmerman D, Bourne T, Valentin L, Epstein E, Goldstein SR et al (2010) Terms, definitions and measurements to describe the sonographic features of the endometrium and intrauterine lesions: a consensus opinion from the International Endometrial Tumor Analysis (IETA) group. Ultrasound Obstet Gynecol 35(1):103–112 CrossRef
14.
Zurück zum Zitat Narice BF, Delaney B, Dickson JM (2018) Endometrial sampling in low-risk patients with abnormal uterine bleeding: a systematic review and meta-synthesis. BMC Fam Pract 19(1):135 CrossRef Narice BF, Delaney B, Dickson JM (2018) Endometrial sampling in low-risk patients with abnormal uterine bleeding: a systematic review and meta-synthesis. BMC Fam Pract 19(1):135 CrossRef
15.
Zurück zum Zitat Pennant ME et al (2017) Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG 124(3):404–411 CrossRef Pennant ME et al (2017) Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG 124(3):404–411 CrossRef
16.
Zurück zum Zitat Saccardi C et al (2013) Endometrial surveillance in tamoxifen users: role, timing and accuracy of hysteroscopic investigation: observational longitudinal cohort study. Endocr Relat Cancer 20(4):455–462 CrossRef Saccardi C et al (2013) Endometrial surveillance in tamoxifen users: role, timing and accuracy of hysteroscopic investigation: observational longitudinal cohort study. Endocr Relat Cancer 20(4):455–462 CrossRef
17.
Zurück zum Zitat Savelli L et al (2008) Preoperative local staging of endometrial cancer: transvaginal sonography vs. magnetic resonance imaging. Ultrasound Obstet Gynecol 31(5):560–566 CrossRef Savelli L et al (2008) Preoperative local staging of endometrial cancer: transvaginal sonography vs. magnetic resonance imaging. Ultrasound Obstet Gynecol 31(5):560–566 CrossRef
18.
Zurück zum Zitat Selman TJ et al (2008) A systematic review of tests for lymph node status in primary endometrial cancer. BMC Womens Health 8:94 CrossRef Selman TJ et al (2008) A systematic review of tests for lymph node status in primary endometrial cancer. BMC Womens Health 8:94 CrossRef
19.
Zurück zum Zitat Singh N, Hirschowitz L, Zaino R, Alvarado-Cabrero I, Duggan MA, Ali-Fehmi R et al (2019) Pathologic prognostic factors in endometrial carcinoma (other than tumor type and grade). Int J Gynecol Pathol 38(Suppl 1):S93–S113 CrossRef Singh N, Hirschowitz L, Zaino R, Alvarado-Cabrero I, Duggan MA, Ali-Fehmi R et al (2019) Pathologic prognostic factors in endometrial carcinoma (other than tumor type and grade). Int J Gynecol Pathol 38(Suppl 1):S93–S113 CrossRef
20.
Zurück zum Zitat Timmermans A et al (2010) Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol 116(1):160–167 CrossRef Timmermans A et al (2010) Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol 116(1):160–167 CrossRef
21.
Zurück zum Zitat Van Den Bosch T, Verbakel JY, Valentin L, Wynants L, De Cock B, Pascual MA et al (2021) Typical ultrasound features of various endometrial pathologies described using International Endometrial Tumor Analysis (IETA) terminology in women with abnormal uterine bleeding. Ultrasound Obstet Gynecol 57(1):164–172 CrossRef Van Den Bosch T, Verbakel JY, Valentin L, Wynants L, De Cock B, Pascual MA et al (2021) Typical ultrasound features of various endometrial pathologies described using International Endometrial Tumor Analysis (IETA) terminology in women with abnormal uterine bleeding. Ultrasound Obstet Gynecol 57(1):164–172 CrossRef
22.
Zurück zum Zitat Verdoodt F, Jiang X, Williams M, Schnatz PF, Arbyn M (2016) High-risk HPV testing in the management of atypical glandular cells: a systematic review and meta-analysis. Int J Cancer 138(2):303–310 CrossRef Verdoodt F, Jiang X, Williams M, Schnatz PF, Arbyn M (2016) High-risk HPV testing in the management of atypical glandular cells: a systematic review and meta-analysis. Int J Cancer 138(2):303–310 CrossRef
23.
Zurück zum Zitat Vermij L, Smit V, Nout R, Bosse T (2020) Incorporation of molecular characteristics into endometrial cancer management. Histopathology 76(1):52–63 CrossRef Vermij L, Smit V, Nout R, Bosse T (2020) Incorporation of molecular characteristics into endometrial cancer management. Histopathology 76(1):52–63 CrossRef
24.
Zurück zum Zitat Woolas R et al (2011) Significant endometrial pathology detected during a transvaginal ultrasound screening trial for ovarian cancer. Gynecol Oncol 120(Supplement 1):S39 CrossRef Woolas R et al (2011) Significant endometrial pathology detected during a transvaginal ultrasound screening trial for ovarian cancer. Gynecol Oncol 120(Supplement 1):S39 CrossRef
25.
Zurück zum Zitat Vasen HF et al (2013) Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62(6):812–823 CrossRef Vasen HF et al (2013) Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62(6):812–823 CrossRef
Metadaten
Titel
Früherkennung, Diagnostik, Bildgebung und Pathologie
verfasst von
Prof. Dr. Eric Steiner
Lars-Christian Horn
Theresa Mokry
Sigurd F. Lax
Doris Mayr
Wolfgang Cremer
Heinrich-Josef Prömpeler
Dieter Grab
Michael Reinhardt
Publikationsdatum
23.06.2022
Verlag
Springer Medizin
Erschienen in
Die Gynäkologie / Ausgabe 7/2022
Print ISSN: 2731-7102
Elektronische ISSN: 2731-7110
DOI
https://doi.org/10.1007/s00129-022-04957-y

Weitere Artikel der Ausgabe 7/2022

Die Gynäkologie 7/2022 Zur Ausgabe

Passend zum Thema

Galenus-Preis-Kandidat 2022 – Specialist Care

Dostarlimab – erste Immuntherapie beim Endometriumkarzinom mit dMMR/MSI-H

Dostarlimab von GlaxoSmithKline ist der erste ImmuncheckpointInhibitor zur Therapie des schwer behandelbaren, rezidivierten oder fortgeschrittenen Endometriumkarzinoms mit Mismatch-Reparatur-Defizienz (dMMR) und hoher Mikrosatelliten-Instabilität (MSI-H).Es können hohe Ansprechraten induziert werden.